- Home
- GWRS vs MRVI Comparison
GWRS vs MRVI Comparison
Compare GWRS & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- MRVI
- Stock Information
- Founded
- GWRS 2003
- MRVI 2014
- Country
- GWRS United States
- MRVI United States
- Employees
- GWRS N/A
- MRVI N/A
- Industry
- GWRS Water Supply
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- GWRS Utilities
- MRVI Health Care
- Exchange
- GWRS Nasdaq
- MRVI Nasdaq
- Market Cap
- GWRS 270.6M
- MRVI 262.9M
- IPO Year
- GWRS 2010
- MRVI 2020
- Fundamental
- Price
- GWRS $10.26
- MRVI $1.93
- Analyst Decision
- GWRS
- MRVI Hold
- Analyst Count
- GWRS 0
- MRVI 9
- Target Price
- GWRS N/A
- MRVI $6.54
- AVG Volume (30 Days)
- GWRS 66.6K
- MRVI 2.7M
- Earning Date
- GWRS 05-07-2025
- MRVI 05-07-2025
- Dividend Yield
- GWRS 2.94%
- MRVI N/A
- EPS Growth
- GWRS N/A
- MRVI N/A
- EPS
- GWRS 0.24
- MRVI N/A
- Revenue
- GWRS $52,692,000.00
- MRVI $259,185,000.00
- Revenue This Year
- GWRS $7.63
- MRVI N/A
- Revenue Next Year
- GWRS $5.58
- MRVI $14.23
- P/E Ratio
- GWRS $42.94
- MRVI N/A
- Revenue Growth
- GWRS N/A
- MRVI N/A
- 52 Week Low
- GWRS $9.37
- MRVI $1.67
- 52 Week High
- GWRS $13.98
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- GWRS 44.75
- MRVI 38.60
- Support Level
- GWRS $10.03
- MRVI $1.67
- Resistance Level
- GWRS $10.46
- MRVI $1.89
- Average True Range (ATR)
- GWRS 0.38
- MRVI 0.17
- MACD
- GWRS 0.05
- MRVI 0.05
- Stochastic Oscillator
- GWRS 72.41
- MRVI 44.54
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.